BioWorld

Feb. 21, 2008

View Archived Issues

Pfizer $195M Deal for Encysive Called a 'Good Deal' For Both

First Working Pancreatic Beta Cells Derived from ESCs

Bioheart Squeezes Out IPO Window with Meager $5.8M

Antisense Licenses MS Drug to Teva for $2M Up Front

Other News To Note

Clinic Roundup

Acceleron, Celgene in Potential $1.8B Bone Loss Collaboration

When it came to signing its first biotech collaboration since being founded in 2003, Acceleron Pharma Inc. made sure it was a big one. (BioWorld Today) Read More

Today's news in brief

BioWorld

BioWorld briefs for June 11, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for June 12, 2025.

AI-generated illustration of heart and metabolic impact

Deep Apple signs big Novo deal for cardiometabolic small molecules

BioWorld

Deep Apple Therapeutics Inc. could bring in as much as $812 million in a new collaboration and license deal with Novo Nordisk A/S. The total includes an...

DNA double helix under a magnifying glass

23andme genetic privacy concerns garner Congressional scrutiny

BioWorld MedTech

The bankruptcy of genetic testing service 23andme Holding Corp. prompted a reaction from many quarters, but a June 11 Senate hearing highlighted an interest in...

3Sbio revs on with phase II data in tight PD-1/VEGF bispecific race

BioWorld

3Sbio Inc. reported interim phase II study results of its PD-1/VEGF bispecific antibody, SSGJ-707 – a “fabulous” asset, according to Pfizer Inc. CEO Albert...